NCT07060547View on ClinicalTrials.gov

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

March 31, 2032

Conditions
Alcoholic HepatitisAlcohol-related Liver Disease
Interventions
DEVICE

HepQuant DuO Test

HepQuant DuO is commercially available in the U.S. as a Laboratory Developed Test (LDT), but it will be used in this study as a nonsignificant risk investigational device to measure change in liver function over time.

Trial Locations (1)

94063

RECRUITING

Stanford University Dept. of Medicine -Gastroenterology & Hepatology, Redwood City

Sponsors

Lead Sponsor

HepQuant, LLC
All Listed Sponsors
collaborator

Leland Stanford Junior University

UNKNOWN

lead

HepQuant, LLC

INDUSTRY

NCT07060547 - Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease | Biotech Hunter | Biotech Hunter